API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. WAR /
  3. RVU.WAR

Ryvu Therapeutics SA (RVU WAR) stock market data APIs

zł43.35 -0.9(-2%) as of November 22, 2024
Price chart is built with Anychart

Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. The company has a research collaboration with Ncage Therapeutics Limited to develop next-generation antibody-drug conjugate (ADC) platform. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Ryvu Therapeutics SA Financial Data Overview

44.25
43.35
-
44.25
43
39.5-67.1
1 002 M
23 116 K
91 179 K
-1.1492
0.648
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RVU',
Type: 'Common Stock',
Name: 'Ryvu Therapeutics SA',
Exchange: 'WAR',
CurrencyCode: 'PLN',
CurrencyName: 'Polish złoty',
CurrencySymbol: 'zł',
CountryName: 'Poland',
CountryISO: 'PL',
OpenFigi: NULL,
ISIN: 'PLSELVT00013',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Ryvu Therapeutics SA Fundamental Data is available in our Financial Data APIs

  • Net Revenue 91 179 K
  • EBITDA -95 245 000
  • Earnings Per Share -4.5
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Ryvu Therapeutics SA Earnings via APIs

  • Latest Release 2024-09-30
  • EPS/Forecast NaN

Get Ryvu Therapeutics SA End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Ryvu Therapeutics SA latest news via APIs

Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

KRAKOW, Poland, July 26, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerg...
  • DIRECTORS AND OFFICERS
  • RYVU THERAPEUTICS
  • WARSAW STOCK EXCHANGE:RVU
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com